ATE237685T1 - Methoden zur identifizierung von individuen, die an einer zellulären abnormalität leiden - Google Patents

Methoden zur identifizierung von individuen, die an einer zellulären abnormalität leiden

Info

Publication number
ATE237685T1
ATE237685T1 AT95913476T AT95913476T ATE237685T1 AT E237685 T1 ATE237685 T1 AT E237685T1 AT 95913476 T AT95913476 T AT 95913476T AT 95913476 T AT95913476 T AT 95913476T AT E237685 T1 ATE237685 T1 AT E237685T1
Authority
AT
Austria
Prior art keywords
methods
individuals suffering
identifying individuals
cellular abnormality
abnormality
Prior art date
Application number
AT95913476T
Other languages
English (en)
Inventor
Pierre Van Der Bruggen
Jean-Pierre Szikora
Pierre Coulie
Claude Wildmann
Pascale Boel
Thierry Boon-Falleur
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/195,186 external-priority patent/US5558995A/en
Priority claimed from US08/196,630 external-priority patent/US5683886A/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE237685T1 publication Critical patent/ATE237685T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT95913476T 1994-02-14 1995-01-26 Methoden zur identifizierung von individuen, die an einer zellulären abnormalität leiden ATE237685T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/195,186 US5558995A (en) 1993-01-22 1994-02-14 Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof
US08/196,630 US5683886A (en) 1993-06-17 1994-02-15 Tumor rejection antigens which correspond to amino acid sequences in tumor rejection antigen precursor bage, and uses thereof
US08/292,492 US6328971B1 (en) 1993-01-22 1994-08-18 MAGE-1 derived nona peptides, and compositions thereof
PCT/US1995/001446 WO1995021630A1 (en) 1994-02-14 1995-01-26 Methods for identifying individuals suffering from a cellular abnormality

Publications (1)

Publication Number Publication Date
ATE237685T1 true ATE237685T1 (de) 2003-05-15

Family

ID=27393408

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95913476T ATE237685T1 (de) 1994-02-14 1995-01-26 Methoden zur identifizierung von individuen, die an einer zellulären abnormalität leiden

Country Status (14)

Country Link
US (1) US6328971B1 (de)
EP (1) EP0789591B1 (de)
JP (1) JP2002502224A (de)
AT (1) ATE237685T1 (de)
AU (1) AU697246B2 (de)
CA (1) CA2182969A1 (de)
DE (1) DE69530410T2 (de)
DK (1) DK0789591T3 (de)
ES (1) ES2197196T3 (de)
FI (1) FI963170A7 (de)
NO (1) NO963347L (de)
NZ (1) NZ282938A (de)
PT (1) PT789591E (de)
WO (1) WO1995021630A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5877017A (en) * 1993-06-17 1999-03-02 Ludwig Institute For Cancer Research Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecule HLA-Cw*1601 and uses thereof
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
EP1117679B9 (de) 1998-10-02 2010-07-07 Ludwig Institute For Cancer Research Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden
US6407063B1 (en) * 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
WO2002044723A2 (en) * 2000-11-28 2002-06-06 Eileen Louise Rice Mcfarland Method for diagnosing a predisposition of psychosis in a progeny

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066783A (en) * 1986-05-20 1991-11-19 Cohen Eric A Antiviral peptides and means for treating herpes infections
CA2101774C (en) * 1991-01-21 2011-01-04 John A. Hardy Test and model for alzheimer's disease
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
US5558995A (en) * 1993-01-22 1996-09-24 Ludwig Institute For Cancer Research Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof
EP0680330A4 (de) * 1993-01-22 1998-07-29 Ludwig Inst Cancer Res Verfahren zur identifikation und behandlung von individuen, die träger von krebszellen sind, die hla-c-klon 10/mage-1 exprimieren.
KR960700739A (ko) * 1993-03-05 1996-02-24 카린 이스텀 Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses)
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
JPH10511639A (ja) * 1994-09-30 1998-11-10 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ 腫瘍拒絶抗原前駆体または腫瘍拒絶抗原を含有する組成物ならびにアジュバント及び／又は成長因子

Also Published As

Publication number Publication date
NZ282938A (en) 2000-01-28
DE69530410D1 (de) 2003-05-22
AU2089995A (en) 1995-08-29
NO963347D0 (no) 1996-08-12
WO1995021630A1 (en) 1995-08-17
FI963170A0 (fi) 1996-08-13
DK0789591T3 (da) 2003-05-19
FI963170L (fi) 1996-08-13
AU697246B2 (en) 1998-10-01
EP0789591A1 (de) 1997-08-20
FI963170A7 (fi) 1996-08-13
ES2197196T3 (es) 2004-01-01
CA2182969A1 (en) 1995-08-17
NO963347L (no) 1996-08-14
US6328971B1 (en) 2001-12-11
EP0789591A4 (de) 1998-07-01
DE69530410T2 (de) 2004-03-25
PT789591E (pt) 2003-08-29
JP2002502224A (ja) 2002-01-22
EP0789591B1 (de) 2003-04-16

Similar Documents

Publication Publication Date Title
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
DE3855525D1 (de) Verwendung eines Protein gebundenen Polysaccharid Zur Herstellung eines Arzneimittels für die Behandlung von AIDS.
ATE252238T1 (de) Methoden für die diagnose von allergischen atemwegsaspergillosen
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
EP0675904A4 (de) Humane neutralisierende monoklonale antikörper gegen den die immunschwäche auslösenden virus aus mensch.
DE69423346D1 (de) Schnelles verfahren fur die dns sequenzierung und diagnostische anwendungen
DE60038993D1 (de) Oligonukleotidprimer zur reversen Transkription für den effizienten Nachweis von HIV-1 und HIV-2 und Methoden ihrer Verwendung
DE69510336D1 (de) Verfahren zur diagnose von praeklampsie
DE69718776D1 (de) Vorrichtung zur Vermeidung von Falten zwischen den Brüsten
NO920125D0 (no) Fremgangsmaate for aa bestemme den funksjonelle aktivitetentil fri protein s eller protein c i en plasma-proeve
BR0014150A (pt) Diagnósticos e terapêuticos para osteoporose
ATE237685T1 (de) Methoden zur identifizierung von individuen, die an einer zellulären abnormalität leiden
NO952385D0 (no) Fremgangsmåte til identifisering av individer med unormale celler som uttrykker HLA-A2/tyrosinasepeptidantigen
NO963487L (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
ATE338142T1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
DE60012140D1 (de) Verwendung von urintrypsininhibitor zur diagnose von aids
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
DE69636041D1 (de) Nachweis von brusttumorvirus-artigen sequenzen in brustkrebs bei menschen
DE69535707D1 (de) Methoden zur behandlung oder diagnose von krankheiten oder zuständen, die mit einer abnormalen signalübertragung assoziiert sind
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
ATE301720T1 (de) Cathepsin-l, dessen präproform und das entsprechende propeptid aus ciliaten
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.
WO2000000510A1 (en) Growth factor modulators
RU97103673A (ru) Способ диагностики иммунодефицита при вич-инфекции

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0789591

Country of ref document: EP